◀ Back to BCL10
BCL10 — MAP2K1
Text-mined interactions from Literome
Lunghi et al., Leukemia 2005
(Leukemia, Promyelocytic, Acute) :
MEK1 inhibitors dephosphorylated Bad and
inhibited the ATO induced increase of
Bcl-xL , overcoming ATO resistance in NB4-As ( R )
Nakamura et al., J Biol Chem 2006
(MAP Kinase Signaling System) :
We found that
MNSFbeta.Bcl-G directly bound to ERKs and
inhibited ERK activation by
MEK1
Ren et al., J Biol Chem 2007
(Leukemia, Myeloid...) :
Shp2E76K induced
Bcl-XL expression was
suppressed by Mek inhibitors and by a dominant negative
Mek1 mutant but not by the phosphoinositide 3-phosphate inhibitor LY294002 and the Akt inhibitor API-2
Elsegood et al., Arterioscler Thromb Vasc Biol 2009
:
MEK1/2 and PI3K activities were also
required for oxLDL induced Bcl-2 and
Bcl-x ( L ) mRNA upregulation
Brinkkoetter et al., J Clin Invest 2009
(Glomerulonephritis) :
Furthermore, we found that levels of phosphorylated MEK1/2 and ERK1/2 were decreased in cyclin I-deficient podocytes and that inhibition of
MEK1/2 restored Bcl2 and
Bcl-XL protein levels